دورية أكاديمية
أعرض في EDS

Seroprevalence of hepatitis B, C, and D and associated factors in the semi-isolated Yanomami Amazonian indigenous community.

التفاصيل البيبلوغرافية
العنوان: Seroprevalence of hepatitis B, C, and D and associated factors in the semi-isolated Yanomami Amazonian indigenous community.
المؤلفون: Vasconcelos MPA; Centro de Medicina Tropical de Rondônia - CEMETRON, Porto Velho, Rondônia, Brazil.; Laboratório de Imunoparasitologia do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil., Sánchez-Arcila JC; Laboratório de Imunoparasitologia do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil., Peres L; Laboratório de Hepatites Virais do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil., de Sousa PSF; Laboratório de Hepatites Virais do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil., Castro-Alves J; Instituto Nacional de Infectologia Evandro Chagas da Fundação Oswaldo Cruz - FIOCRUZ, Rio de Janeiro, Brazil., Albuquerque HG; Laboratório de Doenças Parasitárias do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil., Mendes-Correa MC; Departamento de Moléstias Infecciosas e Parasitárias da Faculdade de Medicina da Universidade de São Paulo - USP, São Paulo, Brazil., Maia-Herzog M; Laboratório de Referência Nacional em Simulídeos, Oncocercose e Mansonelose, Coleção de Simulídeos do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil., Lewis-Ximenez LL; Laboratório de Hepatites Virais do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil., Villar LM; Laboratório de Hepatites Virais do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brazil., Oliveira-Ferreira J; Laboratório de Imunoparasitologia do Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Rio de Janeiro, Brazil. lila@ioc.fiocruz.br.
المصدر: BMC infectious diseases [BMC Infect Dis] 2024 Jan 02; Vol. 24 (1), pp. 15. Date of Electronic Publication: 2024 Jan 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Hepatitis B*/epidemiology , Hepatitis B*/diagnosis , Hepatitis, Viral, Human*/epidemiology , Vaccines* , Hepatitis C*/epidemiology, Child ; Humans ; Adolescent ; Hepatitis B Surface Antigens ; Seroepidemiologic Studies ; Cross-Sectional Studies ; Hepatitis B Antibodies ; Hepatitis B virus ; Hepatitis C Antibodies ; Prevalence
مستخلص: Background: Viral hepatitis is a significant health concern among indigenous population in the Americas. In Brazil, reports find high endemicity of HBV and HDV infections has been reported in several indigenous groups. However, few studies have documented the prevalence of HBV, HCV and HDV in the Yanomami. In this study, the prevalence of hepatitis B, C, and D serological markers and potential risk factors were investigated to provide guidance for the development of strategies aimed at reducing viral transmission in the Yanomami indigenous villages.
Methods: This cross-sectional study was carried out in March 2015 and included 430 individuals from four Yanomami villages: Alapusi (n = 78), Castanha/Ahima (n = 126), Gasolina (n = 105), and Taibrapa (n = 121). A rapid test was used for detection of HBsAg and anti-HCV and chemiluminescent immunoassay for anti-HBs, anti-HBc, and anti-HDV antibodies.
Results: HBsAg, anti-HBc, and anti-HBs were detected in 8.8, 45.5, and 49.4% of the participants, respectively. The estimated HBV status: current infection 9.6% (38/395); resolved infection 43.3% (171/395); vaccine immunity 20.5% (81/395), and susceptible to HBV 26.6% (105/395). Gasolina presented the lowest prevalence of HBV infection (6.5%) and the highest prevalence of vaccine immunity (26.9%). Children < 15 years old were highly susceptible to infection, as 53.1% did not have antibodies to HBV, while more than 80% of individuals over 45 years of age had been exposed to HBV. The markers for HDV were founded among 12.5% (4/32) of the HBsAg carriers. Anti-HCV was identified in all villages, with the highest prevalence in Alapusi (5.1%). Possible risk factors such as the use of piercings, tattoos, and contact with prospectors showed no statistical difference between the groups.
Conclusions: Viral hepatitis B and serological markers for HCV and HDV were found to be widely distributed among the Yanomami indigenous community, while the prevalence of vaccine immunity to HBV was low. This finding reinforces the importance of promoting systematized diagnostic and vaccination strategies in indigenous communities. Our data confirm that isolated and difficult-to-reach indigenous communities lack appropriate access to diagnosis, treatment, and vaccination.
(© 2023. The Author(s).)
References: Trans R Soc Trop Med Hyg. 1988;82(3):469-71. (PMID: 3232188)
Cold Spring Harb Perspect Med. 2015 May 01;5(5):a021410. (PMID: 25934461)
Soc Sci Med. 1996 Jun;42(12):1735-43. (PMID: 8783434)
Gut. 1996;38 Suppl 2:S48-55. (PMID: 8786054)
Hepatology. 2020 Feb;71(2):686-721. (PMID: 31816111)
Trop Med Int Health. 2010 Aug;15(8):924-33. (PMID: 20561309)
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. (PMID: 29599078)
Rev Soc Bras Med Trop. 2012 Jul-Aug;45(4):457-62. (PMID: 22930043)
J Hepatol. 2020 Sep;73(3):523-532. (PMID: 32335166)
Rev Infect Dis. 1991 Jan-Feb;13(1):52-5. (PMID: 2017631)
BMC Infect Dis. 2018 Aug 20;18(1):411. (PMID: 30126364)
Braz J Infect Dis. 2002 Oct;6(5):269-70. (PMID: 12495611)
Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415. (PMID: 35180382)
J Pediatr Nurs. 2022 Jul-Aug;65:e1-e2. (PMID: 35034827)
PLoS One. 2018 May 25;13(5):e0197662. (PMID: 29799873)
Rev Soc Bras Med Trop. 2012 Feb;45(1):9-12. (PMID: 22370821)
Cad Saude Publica. 2007 Nov;23(11):2756-66. (PMID: 17952269)
Rev Soc Bras Med Trop. 2001 Jul-Aug;34(4):349-55. (PMID: 11562728)
Semin Liver Dis. 2012 Aug;32(3):228-36. (PMID: 22932971)
Vaccines (Basel). 2020 Aug 21;8(3):. (PMID: 32839391)
Braz J Infect Dis. 2020 Sep - Oct;24(5):434-451. (PMID: 32926839)
Vaccines (Basel). 2019 Dec 19;8(1):. (PMID: 31861551)
MMWR Recomm Rep. 2023 Mar 10;72(1):1-25. (PMID: 36893044)
Hepatol Res. 2020 Mar;50(3):272-282. (PMID: 31845478)
Rev Soc Bras Med Trop. 2004;37 Suppl 2:9-13. (PMID: 15586891)
Hepatology. 2012 Jul;56(1):76-85. (PMID: 22334419)
فهرسة مساهمة: Keywords: HBV; HCV; HDV; Viral hepatitis; Yanomami
المشرفين على المادة: 0 (Hepatitis B Surface Antigens)
0 (Hepatitis B Antibodies)
0 (Hepatitis C Antibodies)
0 (Vaccines)
تواريخ الأحداث: Date Created: 20240103 Date Completed: 20240105 Latest Revision: 20240106
رمز التحديث: 20240106
مُعرف محوري في PubMed: PMC10762995
DOI: 10.1186/s12879-023-08928-z
PMID: 38166687
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا